In clinical studies, NAP, the ADNP active peptide fragment, has been shown to protect cognitive and functional activity in patients with mild cognitive impairment (Morimoto et al. 2013), as well as in schizophrenia patients (Vaisburd et al. 2015), in women suffering from progressive supranuclear palsy (PSP) (Gozes et al. 2023), and is currently under development for the treatment of ADNP syndrome (Gozes 2024). The gene discussed is ADNP; the disease is schizophrenia.